2.

Baseline characteristics: presence versus absence of paroxysmal atrial fibrillation.

Characteristic	Presence of paroxysmal AF					Absence of paroxysmal AF
	(n = 67)	P-value*	P-value**	P-value#		(n = 206)	P-value*	P-value**
Data are presented as means ± SD or n (%). & Presented as median (interquartile range). *Refers to versus control group. **Refers to versus persistent AF. #Refers to versus absence of AF group. ACEIs: angiotensin-converting enzyme inhibitors; AF: atrial fibrillation; ARBs: angiotensin receptor blocking agents; BMI: body mass index; CCBs: calcium channel blockers; DBP: diastolic blood pressure; Hb: hemoglobin; HDL-c: high-density lipoprotein cholesterol; IVST: interventricular septum thickness; LAD: left atrial diameter; LDL-c: low-density lipoprotein cholesterol; LVEDD: left ventricular end diastolic diameter; LVEF: left ventricular ejection fraction; LVPWT: left ventricular posterior wall thickness; RDW: red cell distribution width; SBP: systolic blood pressure; TG: total cholesterol; WBC: white blood cell.
Age, yrs	57.1 ± 10.3	0.105	0.024	0.001		61.8 ± 10.6	0.001	0.468
Male	58 (86.6%)	0.006	0.438	0.001		119 (57.8%)	0.145	0.001
Smoking	22 (32.8%)	0.434	0.906	0.596		75 (36.4%)	0.678	0.680
Duration of hypertension, yrs	8 (5-10) &	0.067	0.157	0.317		7 (6-11) &	0.001	0.471
BMI, kg/m2	24.7 ± 1.9	0.217	0.219	0.372		24.4 ± 2.4	0.559	0.021
Office heart rate, beats/min	88.4 ± 15.4	0.001	0.212	0.001		73.6 ± 15.9	0.675	0.001
Office SBP, mmHg	144.3 ± 7.0	0.860	0.033	0.533		144.8 ± 5.5	0.163	0.021
Office DBP, mmHg	88.2 ± 9.2	0.860	0.010	0.156		90.2 ± 10.0	0.202	0.161
WBC, ×109/L	5.9 ± 1.4	0.032	0.208	0.189		5.4 ± 1.8	0.001	0.854
Hb, g/L	145.1 ± 15.8	0.045	0.080	0.048		140.6 ± 16.2	0.681	0.001
RDW, %	13.0 ± 0.6	0.001	0.533	0.001		12.5 ± 0.9	0.262	0.001
Creatinine, μmol/L	82.1 ± 13.4	0.029	0.102	0.061		78.0 ± 16.7	0.820	0.001
TG, mmol/L	4.9 ± 0.5	0.180	0.503	0.881		4.9 ± 0.5	0.170	0.355
HDL-c, mmol/L	1.4 ± 0.2	0.016	0.007	0.677		1.4 ± 0.2	0.003	0.001
LDL-c, mmol/L	3.0 ± 0.4	0.714	0.386	0.169		3.1 ± 0.4	0.339	0.735
Triglycerides, mmol/L	1.9 ± 0.4	0.002	0.001	0.001		1.7 ± 0.3	0.093	0.868
Fasting glucose, mmol/L	4.8 ± 0.7	0.673	0.246	0.633		4.8 ± 0.6	0.288	0.335
Na+, mmol/L	141.2 ± 2.5	0.075	0.579	0.532		141.4 ± 2.4	0.114	0.168
K+, mmol/L	4.0 ± 0.3	0.884	0.012	0.669		4.0 ± 0.3	0.510	0.001
LAD, mm	40.1 ± 4.7	0.001	0.001	0.004		38.0 ± 5.4	0.001	0.001
LVEDD, mm	48.6 ± 4.6	0.015	0.839	0.107		47.6 ± 4.7	0.227	0.130
LVPWT, mm	11.4 ± 1.0	0.001	0.223	0.230		11.2 ± 1.4	0.001	0.012
IVST, mm	11.4 ± 1.8	0.001	0.035	0.777		11.5 ± 1.5	0.001	0.008
LVEF, %	62.4 ± 4.6	0.530	0.034	0.479		62.9 ± 4.2	0.802	0.001
ACEIs/ARBs	46 (68.7%)	0.837	0.013	0.130		120 (58.3%)	0.167	0.124
Statins	20 (29.9%)	0.001	0.106	0.543		55 (26.7%)	0.768	0.009
Beta-blockers	28 (41.8%)	0.079	0.977	0.234		80 (38.8%)	0.085	0.677
Diuretics	11 (16.4%)	0.484	0.586	0.638		29 (14.1%)	0.673	0.813
CCBs	31 (46.3%)	0.460	0.001	0.471		85 (41.3%)	0.874	0.001
Propafenone	20 (29.9%)	-	0.735	0.616		55 (26.7%)	-	0.276
Amiodarone	25 (37.3%)	-	0.906	0.097		55 (26.7%)	-	0.112
Digoxin	11 (16.4%)	-	0.723	0.638		29 (14.1%)	-	0.964
Aspirin	34 (50.7%)	0.326	0.747	0.970		104 (50.5%)	0.232	0.716
Anticoagulation drugs	7 (10.4%)	-	0.091	0.301		32 (15.5%)	-	0.295
Warfarin	4 (6.0%)	-	0.156	0.155		25 (12.1%)	-	0.847
Dabigatran/Rivaroxaban	3 (4.5%)	-	0.277	0.683		7 (3.4%)	-	0.049